Objectives: The orexigenic hormone ghrelin circulates mainly in two forms, acylated and desacyl ghrelin. We evaluated the impact of obesity and obesity-associated type 2 diabetes (T2D) on ghrelin forms and the potential role of acylated and desacyl ghrelin in the control of adipogenesis in humans. Methods: Plasma concentrations of the different ghrelin forms were measured in 80 subjects. The expression of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R) was analyzed in omental adipose tissue using western blot and immunohistochemistry, and the effect of acylated ghrelin and desacyl ghrelin (0.1-1000 pmol l À1 ) on adipogenesis was determined in vitro in omental adipocytes. Results: Circulating concentrations of acylated ghrelin were increased, whereas desacyl ghrelin levels were decreased, in obesity and obesity-associated T2D. Body mass index, waist circumference, insulin and HOMA (homeostasis model assessment) index were positively correlated with acylated ghrelin levels. Obese individuals showed a lower protein expression of GHS-R in omental adipose tissue. In differentiating omental adipocytes, incubation with both acylated and desacyl ghrelin significantly increased PPARg (peroxisome proliferator-activated receptor g) and SREBP1 (sterol-regulatory element binding protein-1) mRNA levels, as well as several fat storage-related proteins, including acetyl-CoA carboxylase, fatty acid synthase, lipoprotein lipase and perilipin. Consequently, both the ghrelin forms stimulated intracytoplasmatic lipid accumulation. Conclusions: Both acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Given the lipogenic effect of acylated ghrelin on visceral adipocytes, the herein-reported elevation of its circulating concentrations in obese individuals may play a role in excessive fat accumulation in obesity.
Introduction
Ghrelin is a 28 amino-acid peptide with an n-octanoyl group at the serine 3 residue, produced mainly by the stomach, which was identified as the endogenous ligand of the growth hormone (GH) secretagogue receptor (GHS-R). 1 The total ghrelin levels are decreased in obesity, insulin resistance and type 2 diabetes (T2D). [2] [3] [4] However, ghrelin circulates in two major forms, acylated (B5% of total ghrelin) and desacyl ghrelin (the form lacking n-octanoylation and representing B95% of total ghrelin), with potential differences in their metabolic effects. 5 In addition to its ability to stimulate GH secretion, ghrelin can also stimulate caloric intake and increase body weight and adiposity. [6] [7] [8] Administration of exogenous ghrelin reportedly enhances appetite and increases food intake through the activation of hypothalamic neuropeptide Y/agouti-related peptide neurones expressing GHS-R type 1a. 6, [8] [9] [10] [11] Both activities, GH-release and food intake stimulation, require n-octanoyl modification of ghrelin. 1 In addition, ghrelin controls glucose homeostasis by regulating insulin secretion and sensitivity in pancreatic b-cells 12 and by stimulating glucose output by primary hepatocytes. 13 Furthermore, deletion of ghrelin in obese diabetic ob/ob mice increases basal insulin concentrations, enhances glucose-stimulated insulin secretion and improves peripheral insulin sensitivity. 14 Interestingly, desacyl ghrelin induces a negative energy balance by decreasing food intake in an inverse manner to acylated ghrelin. 15 Moreover, desacyl ghrelin suppresses glucose release by hepatocytes and is able to antagonize the acylated ghrelin-induced increase in hepatic glucose output, 13 as well as the decrease in circulating insulin concentrations. 16 Adipogenesis is a highly controlled process, in which the expression of adipose-specific genes is crucial for inducing differentiation and for determining the phenotypic characteristics of adipocytes. 17 The main transcription factors that control this process include PPARg (peroxisome proliferator-activated receptor g) and SREBP1 (sterol-regulatory element binding protein-1). Differentiated adipocytes take up free fatty acids (FFAs) and glycerol for the biosynthesis of triglycerides. Acylated ghrelin has been shown to increase adiposity in rats by enhancing the expression of fat-storage enzymes, such as lipoprotein lipase (LPL), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS) and stearoyl-CoA desaturase-1, through centrally mediated mechanisms. 6, 18 Moreover, it has been suggested that acylated ghrelin directly acts on adipocytes for stimulating adipogenesis in rodents. [19] [20] [21] Nonetheless, these data are not univocal, as other authors have reported that overexpression of ghrelin inhibits adipocyte differentiation in 3T3-L1 adipocytes, and that the genetic deletion of ghrelin or its receptor in mice induces thymic adipogenesis. 22, 23 These contradictory observations raise some questions regarding the involvement of ghrelin in the control of adipocyte metabolism. Therefore, the aim of this study was to explore the potential differences in circulating ghrelin and desacyl ghrelin concentrations in normal weight, obesity and obesity-associated T2D, as well as to investigate the possibility of a direct peripheral effect of acylated and desacyl ghrelin on human adipocytes. In this regard, both the presence of GHS-R together with the effects of the major isoforms of ghrelin on key regulatory molecules involved in lipogenesis in human visceral adipocytes were studied.
Materials and methods

Patient selection and study design
To analyze the effect of obesity and obesity-associated T2D on acylated ghrelin and desacyl ghrelin concentrations, 80 Caucasian subjects (21 lean and 59 obese) were recruited from healthy volunteers and patients attending the Departments of Internal Medicine and Endocrinology of the Clínica Universitaria de Navarra (Pamplona, Spain). Subjects were classified according to body mass index (lean o25 kg/m 2 ; obese X30 kg/m 2 ). The patients underwent a clinical assessment including medical history, physical examination and comorbidity evaluation, which were carried out by a multidisciplinary consultation team. Normoglycemia, impaired glucose tolerance and T2D are defined following the criteria of the Expert Committee on the Diagnosis and Classification of Diabetes, 24 based on fasting serum glucose concentrations. Fourteen obese subjects with T2D were on oral anti-diabetic agents with inadequate glycemic control (glycated hemoglobin A1c: 7.2 ± 0.1%). Eleven subjects were smokers (1 normal weight and 10 obese) with no significant difference among the four groups for the smoking status (P ¼ 0.155). Baseline characteristics of the subjects included in this study are summarized in Table 1 .
In addition, the presence of the functional ghrelin receptor, GHS-R 1a, as well as the effect of the two main isoforms of ghrelin was assessed in biopsies of the omental depot from 24 female patients undergoing either laparoscopic Roux-en-Y gastric bypass (n ¼ 18) or Nissen funduplication (n ¼ 6). Clinical characteristics of this cohort were essentially the same as reported in Table 1 . Reported investigations were carried out in accordance with the principles of the Declaration of Helsinki that was revised in 2000. The experimental design was approved, from an ethical and scientific standpoint, by the Hospital's Ethical Committee responsible for the research, and volunteers gave their informed consent for participating in the studies.
Analytical procedures
Blood samples were collected after an overnight fast, early in the morning, to avoid the potential confounding influences because of hormonal rhythmicity. Plasma glucose and insulin were analyzed as described earlier. 25 The HOMA (homeostasis model assessment) score of insulin resistance was calculated with the formula: fasting insulin (mU ml
À1
) Â fasting glucose (mmol l À1 )/22.5. 26 An indirect measure of insulin sensitivity was calculated from the fasting glucose and insulin concentrations by using the QUICKI (quantitative insulin sensitivity check index). 27 FFAs were determined using enzymatic spectrophotometric methods (WAKO Chemicals, GmbH, Neuss, Germany). Total and high-density lipoprotein cholesterol, and triglyceride concentrations were quantified as described earlier. 25 Low-density lipoprotein cholesterol was calculated using the Friedewald formula. Uric acid, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and g-glutamyltransferase were determined using enzymatic tests (Roche, Basel, Switzerland) in an automatic analyzer (Roche/Hitachi Modular P800). Acylated and desacyl ghrelin were determined using ELISA (enzyme-linked immonosorbent assay, LINCO Research, St Charles, MO, USA) following the manufacturer's guidelines, with intra-and inter-assay coefficients of variation being 5.5 and 2.6%, respectively, for the former, and 4.7 and 4.2%, respectively, for the latter.
Immunohistochemistry of GHS-R 1a
Immunohistochemical detection of the GHS-R 1a protein was carried out in omental adipose tissue, as described supplemented with 2% bovine serum albumin (BSA) (Sigma) and with 2 mg ml À1 collagenase (Roche). Digestion was stopped when the adipocyte medium supplemented with 10% newborn calf serum (NCS) (Sigma) was added, and suspended cells were then filtered through a 100-mm nylon cell strainer (BD Biosciences, Erembodegem, Belgium) and centrifuged for 10 min at 600 g. Adipocytes were decanted and stromovascular pellets were resuspended in the adipocyte medium supplemented with 10% NCS. After a filtration through a 70-mm nylon cell strainer (BD Biosciences), cells were spun at 400 g for 5 min. The stromovascular fraction cells were resuspended in erythrocyte lysis buffer (0.154 mol l
À1
NH 4 Cl, 10 mmol l À1 KHCO 3 , 0.1 mmol l À1 ethylenediaminetetraacetic acid, EDTA) and allowed to settle for 10 min at room temperature, followed by a centrifugation for 10 min at 400 g. The cell pellet was resuspended in the adipocyte medium supplemented with 10% NCS. The stromovascular fraction cells were grown in six-well plastic plates (5 Â 10 4 cells per well) and maintained at 37 1C in a humidified atmosphere with 95% air:5% CO 2 . Adipocyte differentiation was initiated when cells reached B80-90% confluence. Cells were stimulated with differentiation medium I (adipocyte medium supplemented with 10% NCS, 0.5 mmol l À1 3-isobutyl-1-methylxanthine, 0.1 mmol l À1 dexamethasone and 10 mg ml À1 insulin) for 2 days. Furthermore, the cells were then switched to Uric acid (mg per 100 ml)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FFA, free fatty acids; g-GT, g-glutamyltransferase; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; IGT, impaired glucose tolerance; LDL, low-density lipopreotein; NG, normoglycaemia; T2D, type 2 diabetes; QUICKI, quantitative insulin sensitivity check index. Values presented as the mean ± s.e.m. Differences among groups were analyzed by one-way ANOVA followed by Scheffé's test. *Po0.05 vs lean NG subjects, **Po0.05 vs obese NG patients. ) for 48 h. One sample per experiment was used for obtaining control responses in the presence of a solvent.
RNA extraction and real-time PCR
Total RNA from differentiated adipocytes was extracted as described earlier. 25 The transcript levels for PPARG and SREBF1 genes were quantified by real-time PCR (7300 Real Time PCR System, Applied Biosystems, Foster City, CA, USA). Primers and probes (Sigma) were designed using the software Primer Express 1.0 (Applied Biosystems). Primers used to amplify the cDNA of PPARG (NM_138712) were 5 0 -GGGATGTCTCATAATGCCATCAG-3 0 and 5 0 -AAGGAGAA GCTGTTGGCGG-3 0 , and the probe was 5 0 -FAM-TTTGGGCG GATGCCACAGGC-TAMRA-3 0 , whereas the primers used to amplify the cDNA of SREBF1 (NM_004176) were 5 0 -ACATCG AAGACATGCTTCAGCTT-3 0 and 5 0 -TTTGACCCACCCTATGC TGG-3 0 , and the probe was 5 0 -FAM-CAACAACCAAGACAG TGACTTCCCTGGC-TAMRA-3 0 . The cDNA was amplified at the following conditions: 95 1C for 10 min, followed by 45 cycles of 15 s at 95 1C and 1 min at 59 1C, using the TaqMan Universal PCR Master Mix (Applied Biosystems). The primer and probe concentrations were 300 and 200 nmol l À1 , respectively. All results were normalized for the expression of 18S rRNA (Applied Biosystems), and relative quantification was calculated using the DDC T formula. 25 The relative mRNA expression was expressed as fold expression over the calibrator sample (average of gene expression corresponding to unstimulated adipocytes). All samples were run in triplicate and the average values were calculated.
Western blot studies Cells and tissues were homogenized and protein content was measured as described earlier. 29 Thirty micrograms of total protein were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) under denaturing conditions, transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and blocked in TBS with 0.05% Tween 20 (TBS-T) containing 5% non-fat dry milk for 1 h at room temperature. Blots were then incubated overnight at 4 1C with primary antibodies against GHS-R (Alpha Diagnostic International), aquaporin-7 (AQP7) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), FAS (Cell Signaling, Danver, MA, USA), adipophilin (Acris, Hiddenhausen, Germany), perilipin (Acris) or b-actin (Sigma). The antigen-antibody complexes were visualized using horseradish peroxidase-conjugated anti-rabbit, anti-mouse or anti-guinea pig IgG antibodies (1:5000) and the enhanced chemiluminescence ECL Plus detection system (Amersham Biosciences). The intensity of the bands was determined by densitometric analysis with the Gel Doc gel documentation system and with the Quantity One 4.5.0 software (Bio-Rad) and normalized with b-actin density values. All assays were carried out in duplicate.
Measurement of intracellular lipid accumulation
Cellular triglyceride content was measured using enzymatic methods, in accordance with earlier-published procedures. 
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Statistical analysis Data are expressed as mean±s.e.m. Statistical differences among mean values were determined using the one-way ANOVA (analysis of variance), followed by Scheffé's t-tests.
For n values per group o10, the non-parametric KruskalWallis test, followed by Mann-Whitney's U pairwise comparisons were applied. Pearson's correlation coefficients (r) were computed for exploring the relation between two variables. A P-value o0.05 was considered statistically significant. Statistics were calculated using SPSS/Windows version 15.0 software (SPSS Inc., Chicago, IL, USA).
Results
Plasma acylated ghrelin and desacyl ghrelin concentrations in obesity and obesity-associated type 2 diabetes Obese subjects showed increased circulating concentrations of acylated ghrelin (obese 6.1±0.5, lean 3.4±0.6 pmol l À1 , Po0.01) and decreased circulating concentrations of desacyl ghrelin (obese 89.9 ± 7.9, lean 172.3 ± 21.5 pmol l À1 , Po0.001) compared with lean individuals (Figure 1) . Furthermore, acylated ghrelin levels were higher (Po0.01) in obese individuals with impaired glucose tolerance (5.2 ± 0.8 pmol l ). No effect of glucose intolerance or diabetes was observed in circulating desacyl ghrelin concentrations (P ¼ 0.124 and P ¼ 0.104, respectively). Neither plasma ghrelin (P ¼ 0.524) nor plasma desacyl ghrelin (P ¼ 0.242) levels were modified by oral anti-diabetic treatment. A clear difference in the relative ratio of both the circulating ghrelin forms was observed. Although lean volunteers showed B3% of acylated ghrelin and B97% of desacyl ghrelin, in obese individuals, the relative amounts changed to B10% in the acylated form and B90% in the desacylated form of the hormone.
Plasma desacyl ghrelin concentrations were increased in women compared with men in the lean group (women 192.5±13.6, men 133.3±13.8 pmol l
À1
, Po0.001), as well as in the obese group (women 104.3 ± 12.1, men 88.6 ± 9.4 pmol l À1 , Po0.001). This sexual dimorphism was neither found in plasma acylated ghrelin of the lean subjects (women 3.5 ± 0.5, men 3.5 ± 0.6 pmol l
, P ¼ 0.538) nor in the obese patients (women 4.9 ± 0.5, men 5.6 ± 0.4 pmol l À1 , P ¼ 0.524). A highly significant positive correlation was observed between acylated ghrelin and body weight, waist circumference and HOMA, whereas desacyl ghrelin showed a strong negative correlation with these parameters (Table 2) . Acylated and desacyl ghrelin levels were significantly correlated with other metabolic variables, as shown in Table 2 .
GHS-R expression in visceral adipose tissue
To analyze whether the adipose tissue constitutes a target for the metabolic effects of ghrelin, the presence of GHS-R in the omental adipose tissue of 24 females was evaluated by immunohistochemistry. A positive black staining for GHS-R was observed in fully mature adipocytes and in the SVFC of omental fat depots of obese patients with normoglycemia, impaired glucose tolerance and T2D (Figure 2a) . The expression of GHS-R protein was further confirmed by western blot analysis with obese patients showing a reduced (Po0.01) GHS-R expression compared with that of lean subjects (Figure 2b) . The GHS-R protein levels were lower in obese individuals with T2D than in obese normoglycemic patients, but the differences fell out of statistical significance (P ¼ 0.338).
Effect of acylated and desacyl ghrelin on lipid accumulation in differentiating visceral adipocytes To determine whether acylated and desacyl ghrelin directly affect adipocyte metabolism, differentiating visceral adipocytes were exposed to increasing concentrations of acylated . Differences among groups were analyzed by one-way ANOVA followed by Scheffé's test. *Po0.05, **Po0.01, ***Po0.001 vs lean NG subjects; w Po0.05, vs obese NG subjects. NG, normoglycemia; IGT, impaired glucose tolerance; T2D, type 2 diabetes; ANOVA, analysis of variance. Lipogenic effect of ghrelin in humans A Rodríguez et al and desacyl ghrelin (0.1-1000 pmol l À1 ) for 48 h. The effect on adipogenesis was assessed by examining the mRNA expression of PPARG, an important adipogenic transcription factor, 32 whereas the impact on lipogenesis was evaluated by studying SREBF1, a transcription factor involved in the de novo synthesis of FFA. 33 The lipid accumulation accompanying these biological processes was assessed by Oil Red O staining and by enzymatic methods. The addition of acylated and desacyl ghrelin during adipocyte differentiation induced a significant increase (Po0.05) in PPARG and SREBF1 transcript levels ( Figure 3) . Similarly, the proportion of cells positive for lipid droplets was markedly increased in the presence of both ghrelin forms, compared with the cells in the differentiation medium without ghrelin ( Figure 4 ). In this sense, acylated and desacyl ghrelin significantly stimulated (Po0.05) lipid accumulation in visceral adipocytes in a concentration-dependent manner ( Figure 4 ). The protein expression of GHS-R in lean NG subjects was assumed to be 1. Values are the mean ± s.e.m. (n ¼ 6 per group). Differences among groups were analyzed using the Kruskal-Wallis test, followed by Mann-Whitney's U pairwise comparisons. *Po0.05, **Po0.01 vs lean NG subjects. GHS-R, growth hormone secretagogue receptor; NG, normoglycemia; IGT, impaired glucose tolerance; T2D, type 2 diabetes.
Lipogenic effect of ghrelin in humans A Rodríguez et al
To establish the potential mechanism of action triggered by acylated ( Figure 5 ) and desacyl ( Figure 6 ) ghrelin for promoting lipid accumulation, several relevant fat storagerelated proteins were evaluated. In accordance with the observed adipogenic action, acylated and desacyl ghrelin increased the expression of perilipin, which coats lipid droplets of mature adipocytes, and reduced adipophilin levels, the protein coating lipid droplets of preadipocytes. Both the ghrelin forms downregulated (Po0.05) the expression of AQP7, which is involved in the transport of glycerol across the plasma membrane. In addition, acylated and desacyl ghrelin upregulated (Po0.01) ACC, the enzyme responsible for the synthesis of malonyl-CoA, FAS, the enzyme that catalyzes the synthesis of long-chain fatty acids from malonyl-CoA and LPL, the enzyme that hydrolyzes fatty acids from the triglyceride-rich core of very low-density lipoproteins and chylomicrons.
Discussion
Acylated ghrelin induces adiposity indirectly by increasing food intake through the activation of hypothalamic neuropeptide Y/agouti-related peptide neurones. 6, [9] [10] [11] Earlier studies suggest that the adipose tissue also constitutes an important target for the adipogenic actions of ghrelin in rodents. 19, 21 This study has explored whether acylated and desacyl ghrelin directly act on visceral adipose tissue for regulating adipocyte metabolism in humans. The main findings are that: (1) circulating acylated ghrelin concentrations are increased in obese patients; (2) GHS-R 1a is expressed in omental adipose tissue; (3) the expression of this ghrelin receptor is decreased in obesity and obesityassociated T2D; and (4) acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Circulating total ghrelin concentrations are decreased in obesity and obesity-associated T2D. [2] [3] [4] However, the potential differences between the different ghrelin forms under these pathophysiological conditions are controversial and remain largely undefined. [34] [35] [36] [37] [38] As expected, our data show decreased plasma desacyl ghrelin levels in obese patients, which is in accordance with studies carried out by other authors. [34] [35] [36] [37] [38] Nonetheless, we found, for the first time, that plasma acylated ghrelin levels are increased in obesity and obesity-associated T2D. The elevation of circulating acylated ghrelin concentrations in obese individuals may play a role in obesity-associated hyperphagia and adiposity. Interestingly, a positive correlation between acylated ghrelin levels with both body mass index and waist circumference was observed. In this regard, given that the visceral adipose tissue . Differences among groups were analyzed using the Kruskal-Wallis test, followed by Mann-Whitney's U pairwise comparisons. *Po0.05, **Po0.01 vs unstimulated adipocytes. PPARG, peroxisome proliferator-activated receptor g; SREBF1, sterol-regulatory element binding factor-1.
Lipogenic effect of ghrelin in humans A Rodríguez et al constitutes a source of ghrelin, 39 excessive abdominal adiposity may contribute to the increase in acylated ghrelin levels found in obese individuals. Increased levels of acylated ghrelin have also been related to hyperglycemia, hyperinsulinemia and the degree of insulin resistance, which is in accordance with data published by other authors. 34, 40 Insulin infusion at pharmacological doses (resulting in serum insulin levels of 1200 pmol l
À1
) throughout a 120 min euglycemic-hyperinsulinemic clamp decreased acylated ghrelin in patients with T2D. 41 Similar suppression of plasma acylated ghrelin has been observed in insulinsensitive vs insulin-resistant obese subjects infused with supraphysiological doses of insulin (75 mU m 2 min) throughout 180-min clamps. 42 Nonetheless, euglycemic hyperinsulinemia using more physiological insulin doses (40 mU m 2 min, resulting in serum insulin levels below 400 pmol l
) significantly decreased the total and desacyl ghrelin, as expected, but not acylated ghrelin, which even tended to increase throughout prolonged (300 min) euglycemic-hyperinsulinemic clamps. 40 Given that obese subjects are more prone to develop insulin resistance than non-obese subjects, increased levels of acylated ghrelin in obese subjects, as observed in this study, may be well explained by a direct effect of hyperinsulinemia. The differential association of acylated ghrelin and desacyl ghrelin with insulin sensitivity is supported by several in vitro and in vivo studies. Ghrelin forms display an opposite impact on glucose output in primary cultures of porcine hepatocytes. 13 In addition, desacyl ghrelin counteracts the influence of acylated ghrelin on insulin secretion and on glucose metabolism in young male volunteers. 16 Furthermore, acylated ghrelin and desacyl ghrelin displayed correlations of opposite sign with variables regarding cholesterol metabolism and hepatic function, underpinning the divergent effects of both forms on metabolic processes. Putative mechanisms for the elevated circulating acylated ghrelin concentrations include increased ghrelin acylation and/or increased ghrelin synthesis and secretion. The factors regulating ghrelin acylation have been largely unknown, although increased availability of the FFA has been proposed to enhance the hormone acylation in mice. 43 Interestingly, Yang et al. 44 have recently identified a novel enzyme implicated in the n-octanoylation of ghrelin, namely GOAT (Ghelin O-Acyltransferase), that is expressed in the major ghrelin-secreting tissues, such as the stomach and intestine. It seems plausible that obesity influences the expression and/or activity of this acyltranferase, leading to elevated plasma concentrations of acylated ghrelin. To our knowledge, this study shows, for the first time, the presence of the functional ghrelin receptor, GHS-R 1a, in human visceral adipose tissue. GHS-R belongs to the family of G protein-coupled receptors and exists in two different isoforms generated by alternative splicing: GHS-R 1a (366 amino acids with 7 transmembrane domains) and GHS-R 1b (289 amino acids with only the first 5 transmembrane domains). 45 GHS-R 1a is considered the functional, signal transducing form of the ghrelin receptor, whereas GHS-R 1b is apparently devoid of high-affinity ligand binding and fails to exhibit any ghrelin-mediated biological activity. 45 In this study, GHS-R 1a immunoreactivity was found in both fully mature adipocytes and SVFCs. In this regard, GHS-R is reportedly expressed in rat adipocytes and in other cell types of the stromovascular fraction, such as rat preadipocytes, human endothelial cells, monocyte-macrophages or T cells. 19, 46, 47 Moreover, a decrease in the GHS-R 1a protein expression in the visceral adipose tissue of obese individuals Lipogenic effect of ghrelin in humans A Rodríguez et al was observed. A plausible explanation for this finding may be that acylated ghrelin, which is increased in obese subjects, downregulates its own receptor in visceral adipocytes, as it does in several cell types, such as chicken and porcine pituitary somatotropes 48, 49 or rat hypothalamic neurones. 50 Our results and those described in other species indicate that GHS-R seems to be rapidly downregulated after binding of its ligand. Taken together, the expression of both ghrelin and its functional receptor, GHS-R 1a, in the visceral fat depot provides evidence for an autocrine-paracrine effect of ghrelin in the human adipose tissue. We investigated the effect of acylated and desacyl ghrelin on lipid accumulation in human visceral adipocytes. In this study, we found that acylated and desacyl ghrelin increased the mRNA expression of PPARg, an important adipogenic transcription factor. 17 In addition, both forms of ghrelin induced the characteristic lipid accumulation accompanying preadipocyte differentiation. It has been reported that after adipogenesis, adipocyte lipid droplets lose their adipophilin coating and acquire a coat of perilipin. 51 In line with this, our findings show that acylated and desacyl ghrelin treatment reduced adipophilin levels, the protein surrounding lipid droplets of preadipocytes, and increased the expression of perilipin, the protein coating lipid droplets in mature adipocytes. On the basis of our results, as well as on the studies carried out in experimental models, [19] [20] [21] it can be concluded that acylated and desacyl ghrelin directly increase adiposity in human visceral adipocytes, independently of its orexigenic action.
To gain further insight into the adipogenic effect of acylated and desacyl ghrelin, the molecular mechanisms whereby the hormone promotes lipid accumulation were evaluated. On the one hand, the lipolysis-derived glycerol is transported to the extracellular medium through the glycerol channel AQP7. 32 Our data show that the expression of AQP7 in human visceral adipocytes is repressed by Lipogenic effect of ghrelin in humans A Rodríguez et al acylated and desacyl ghrelin. The decrease in AQP7 might reflect an overall decreased lipolytic capacity, thereby promoting the maintenance of lipid stores and a progressive adipocyte hypertrophy. 52, 53 On the other hand, de novo synthesis of the FFA or lipogenesis produced in adipocytes further contributes to fat accumulation. SREBP1 (originally named ADD1, adipocyte determination and differentiation dependent factor 1) is a transcription factor that regulates the expression of lipogenic genes. 33 During adipocyte differentiation, SREBP1 is activated and translocated into the nucleus, in which it recognizes sterol response elements and induces the expressions of lipogenic enzymes, including ACC, FAS and LPL. 54 In this study, the stimulation with acylated or desacyl ghrelin in human visceral adipocytes leads to an increase in the SREBP1 mRNA expression. Accordingly, acylated and desacyl ghrelin treatment enhances the protein expressions of ACC, FAS and LPL. A similar upregulation of these enzymes induced by ghrelin has been shown in rat adipose tissue through a mechanism mediated by the sympathetic nervous system. 18 Adipose triglycerides are mainly derived from dietary sources, based on the delivery of fatty acids through LPL-mediated lipolysis of chylomicrons and glucose, both provided in abundance by high-fat diets. Taken together, acylated and desacyl ghrelin stimulate adipose tissue hypertrophy by different mechanisms: (a) by decreasing glycerol output through AQP7, and, hence, decreasing the overall lipolytic capacity; (b) by increasing the FFA uptake into adipocytes through LPL-mediated hydrolysis of circulating lipoproteins; (c) and by promoting the expression of fat-storage enzymes, such as ACC and FAS.
In conclusion, our data provide evidence, for the first time, that acylated and desacyl ghrelin directly stimulate lipid accumulation in human visceral adipocytes, independently of the global orexigenic action of ghrelin. This lipogenic effect together with the elevated acylated ghrelin levels 
Lipogenic effect of ghrelin in humans
A Rodríguez et al found in obese individuals may contribute to the excessive visceral fat accumulation observed in these patients.
